NASDAQ:BDSIBioDelivery Sciences International Stock Price, Forecast & News

BioDelivery Sciences International's stock was trading at $3.96 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BDSI stock has increased by 23.2% and is now trading at $4.88. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioDelivery Sciences International in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BioDelivery Sciences International.

BioDelivery Sciences International is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for BioDelivery Sciences International.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) issued its quarterly earnings data on Thursday, May, 7th. The specialty pharmaceutical company reported $0.05 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.01 by $0.04. The specialty pharmaceutical company earned $38.28 million during the quarter, compared to the consensus estimate of $33.19 million. BioDelivery Sciences International had a negative net margin of 5.01% and a positive return on equity of 23.61%. View BioDelivery Sciences International's earnings history.

8 brokerages have issued twelve-month target prices for BioDelivery Sciences International's stock. Their forecasts range from $8.00 to $9.25. On average, they anticipate BioDelivery Sciences International's share price to reach $8.71 in the next twelve months. This suggests a possible upside of 78.4% from the stock's current price. View analysts' price targets for BioDelivery Sciences International.

Press coverage about BDSI stock has trended negative on Tuesday, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. BioDelivery Sciences International earned a news sentiment score of -2.3 on InfoTrie's scale. They also gave media stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutBioDelivery Sciences International.

Some companies that are related to BioDelivery Sciences International include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Allergan (AGN), Zoetis (ZTS), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioDelivery Sciences International investors own include TG Therapeutics (TGTX), Eldorado Gold (EGO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Alibaba Group (BABA), Baidu (BIDU), JD.Com (JD), Crispr Therapeutics (CRSP) and Gilead Sciences (GILD).

BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."

BioDelivery Sciences International's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.43%), Systematic Financial Management LP (2.39%), Emerald Advisers LLC (2.18%), State Street Corp (1.92%), Emerald Mutual Fund Advisers Trust (1.98%) and Nuveen Asset Management LLC (1.71%). Company insiders that own BioDelivery Sciences International stock include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, James Vollins, Mark A Sirgo, Mary Theresa Coelho, Paolantonio Ernest Robert De, Scott M Plesha and Thomas B Smith. View institutional ownership trends for BioDelivery Sciences International.

BDSI stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Deutsche Bank AG, Two Sigma Investments LP, Assenagon Asset Management S.A., BlackRock Inc., Bank of New York Mellon Corp, WINTON GROUP Ltd, and Squarepoint Ops LLC. Company insiders that have sold BioDelivery Sciences International company stock in the last year include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, James Vollins, Mark A Sirgo, Mary Theresa Coelho, Scott M Plesha, and Thomas B Smith. View insider buying and selling activity for BioDelivery Sciences International.

BDSI stock was acquired by a variety of institutional investors in the last quarter, including Penn Capital Management Co. Inc., Stonepine Capital Management LLC, AQR Capital Management LLC, Systematic Financial Management LP, Grandeur Peak Global Advisors LLC, DG Capital Management LLC, Los Angeles Capital Management & Equity Research Inc., and Cadence Capital Management LLC. View insider buying and selling activity for BioDelivery Sciences International.

Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BDSI stock can currently be purchased for approximately $4.88.

BioDelivery Sciences International has a market capitalization of $487.51 million and generates $111.39 million in revenue each year. The specialty pharmaceutical company earns $-15,310,000.00 in net income (profit) each year or $0.10 on an earnings per share basis. BioDelivery Sciences International employs 178 workers across the globe.

The official website for BioDelivery Sciences International is www.bdsi.com.

BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at 919-582-9050 or via email at [email protected]